

---


## Question

With regard to Health Canada, Public Health Agency of Canada and National Advisory Committee on Immunization expenditures between 2020 and 2023: (a) which projects and departments researched the safety of the COVID-19 vaccines and how much did each project cost, broken down by (i) project name, (ii) department name, (iii) start date, (iv) completion date, (v) cost; (b) which projects and departments researched manufacturers' COVID-19 vaccine applications and how much did each project cost, broken down by (i) vaccine name, (ii) project name, (iii) department name, (iv) start date, (v) completion date, (vi) cost; (c) which projects and departments informed Canadians and specialists about the adverse events associated with the COVID-19 vaccines, broken down by (i) project name, (ii) department name, (iii) adverse event, (iv) start date, (v) completion date, (vi) date Canadians were informed about the adverse event, (vii) cost; and (d) which projects and departments researched vaccine hesitancy and how much did each project cost, broken down by (i) project name, (ii) department name, (iii) start date, (iv) completion date, (v) cost?

---

## Response

This response was tabled in the House of Commons on April 13, 2026, as Sessional Paper 8555-451-848.



### Order/Address of the House of Commons

---

Question number  
Q-848

Asked by  
Dean Allison (Niagara West)

Date asked  
February 9, 2026

---

## Health Canada

Reply by: the Minister of Health

Name of Signatory: Maggie Chi

Reply

## Health Canada

(a) which projects and departments researched the safety of the COVID-19 vaccines and how much did each project cost, broken down by (i) project name, (ii) department name, (iii) start date, (iv) completion date, (v) cost; (b) which projects and departments researched manufacturers' COVID-19 vaccine applications and how much did each project cost, broken down by (i) vaccine name, (ii) project name, (iii) department name, (iv) start date, (v) completion date, (vi) cost; (c) which projects and departments informed Canadians and specialists about the adverse events associated with the COVID-19 vaccines, broken down by (i) project name, (ii) department name, (iii) adverse event, (iv) start date, (v) completion date, (vi) date Canadians were informed about the adverse event, (vii) cost; and (d) which projects and departments researched vaccine hesitancy and how much did each project cost, broken down by (i) project name, (ii) department name, (iii) start date, (iv) completion date, (v) cost?

Before a vaccine is authorized, the Department reviews extensive data filed by the sponsors, including results of clinical trials to assess vaccine safety, quality and efficacy in preventing or treating diseases. Health Canada does so through a rigorous scientific review process. Vaccine reviews are conducted by scientific and medical experts and are grounded in established regulatory standards for human vaccines in Canada.

Once vaccines are authorized, Health Canada releases information about the vaccine, including summaries of the data considered by Health Canada. This includes non-clinical, clinical and other studies, as well as how the decision was made. In relation to COVID-19 vaccines specifically, this information can be found on Health Canada's website at [COVID-19 vaccines and treatments portal](#).



More information on these standards and how Health Canada regulates vaccines for human use in Canada can be found at: [Regulating vaccines for human use in Canada - Canada.ca](https://www.canada.ca/en/health-canada/services/vaccines-and-biologics/standards-requirements-approval-process/standards-requirements-approval-process.html).

## Public Health Agency of Canada

(a) which projects and departments researched the safety of the COVID-19 vaccines and how much did each project cost, broken down by (i) project name, (ii) department name, (iii) start date, (iv) completion date, (v) cost?

In April 2020, the Government of Canada and the Public Health Agency of Canada, set up the COVID-19 Immunity Task Force, a \$300 million Grants and Contributions program in response to the emerging pandemic and a need for serological estimates of the number of Canadians infected with SARS-CoV2 to guide pandemic decision making.

Over its lifespan, the COVID-19 Immunity Task Force generated research to underpin evidence-based decision around the COVID-19 pandemic response. COVID-19 Immunity Task Force serosurveys provided the only nationally representative picture of seroprevalence for COVID-19 in Canada. Insights have also contributed to a greater understanding of the safety and effectiveness of vaccines across different sub-populations, and the extent of immune protection arising from infection and/or vaccination.

The COVID-19 Immunity Task Force generated the following research:

(i) Project Name	(ii) Department Name	(iii) Start Date	(iv) Completion Date	(v) Cost
Monitoring the immune response in the context of COVID-19 vaccination – Establishment of a longitudinal cohort of plasma donors	Public Health Agency of Canada	2021-04-01	2024-03-31	\$925,737.00
CANVAS: COVID Vaccine Active Safety Surveillance	Public Health Agency of Canada	2021-04-01	2023-09-30	\$6,862,814.00
REinfection in COVID19 Estimation of Risk (RECOVER)_Phase 2/Vaccine	Public Health Agency of Canada	2021-04-01	2023-12-31	\$1,363,040.00
The Prevent COVID in Seniors Study: PRospEctiVe EvaluatioN of immuniTy after COVID-19 vaccines in Seniors	Public Health Agency of Canada	2021-04-01	2023-09-30	\$1,930,600.00
Immunogenicity and adverse events following immunization with alternate schedules of authorized COVID-19 vaccines in Canada: is “mix and match” of the second dose safe and immunogenic?	Public Health Agency of Canada	2021-04-01	2023-09-30	\$7,347,523.00
Active surveillance for COVID-19 vaccine safety and effectiveness among Canadian children: A Canadian Immunization Monitoring Program ACTive Project	Public Health Agency of Canada	2021-04-01	2023-12-31	\$2,800,836.00

Canadian COVID-19 Emergency Department Rapid Response Network: Real-World Vaccine Effectiveness and Duration of Protection in Special Populations	Public Health Agency of Canada	2021-04-01	2023-09-30	\$2,943,525.00
Evaluating the safety and immunogenicity of SARS-CoV-2 vaccines among underserved urban populations with intersecting risk factors for COVID-19 morbidity and mortality: a pooled analysis of three prospective cohort studies in Vancouver, Canada	Public Health Agency of Canada	2021-04-01	2023-09-30	\$768,212.00
Optimizing COVID-19 immunization in patients with adverse events following immunization and patients with immunosuppression in the Special Immunization Clinic Network	Public Health Agency of Canada	2021-04-01	2023-09-30	\$808,818.00
A prospective multi-site observational study of SARS-CoV-2 vaccination immunogenicity in patients with hematologic malignancies	Public Health Agency of Canada	2021-04-01	2023-09-30	\$3,001,142.00
Investigating Vaccine Access, Immunogenicity, Effectiveness, and Safety among South Asians in Ontario and British Columbia	Public Health Agency of Canada	2021-04-01	2023-12-31	\$1,905,836.00
Toward Enhancing COVID-19 Vaccine Confidence among African Canadians: Sustainability of Immune Responses and Safety Profiles.	Public Health Agency of Canada	2021-04-01	2023-09-30	\$1,498,686.00
Vaccine Access, Uptake, Effectiveness and Safety in First Nations Communities	Public Health Agency of Canada	2021-04-01	2024-03-31	\$1,497,163.00
Prospective Evaluation of COVID-19 Vaccine in Transplant Recipients: A National Strategy	Public Health Agency of Canada	2021-04-01	2023-12-31	\$2,860,721.00
Canadian COVID-19 Vaccine Registry for Pregnant and Lactating Individuals: An Evaluation of Safety, Effectiveness, and Acceptability	Public Health Agency of Canada	2021-04-01	2023-03-31	\$797,003.00
Safety immunogenicity of Covid-19 vaccines in systemic immune mediated inflammatory Diseases	Public Health Agency of Canada	2021-04-01	2023-09-30	\$3,654,484.00
Determining the safety and effectiveness of COVID-19 vaccination in the chronic kidney disease population	Public Health Agency of Canada	2021-04-01	2023-09-30	\$2,582,588.00
Assessing the impact of the current SARS-CoV-2 vaccine in Indigenous populations in Arctic Canada	Public Health Agency of Canada	2021-04-01	2024-03-31	\$5,753,564.00
Are there postvaccination antibody levels that correlate with protection against COVID-19? (AB-Protect)	Public Health Agency of	2021-04-01	2023-12-31	\$1,578,486.00

	Canada			
COVID-19 Vaccine Immunogenicity and Safety in ImmunoDeficient patients	Public Health Agency of Canada	2021-04-01	2023-12-31	\$2,468,279.00
Fine analysis of longitudinal immune responses to SARS-CoV-2 in vaccination: Harnessing the power of 'Stop The Spread Ottawa' to understand immune protection in COVID-19	Public Health Agency of Canada	2021-04-01	2023-12-31	\$1,725,000.00
COVID-19 Vaccination among People Living with HIV: Immunogenicity, Effectiveness, and Safety	Public Health Agency of Canada	2021-04-01	2023-09-30	\$2,320,124.00
Sentinel surveillance for serious adverse events following immunization and assessment of COVID-19 vaccine effectiveness for the prevention of serious outcomes among hospitalized Canadian adults: A study of the Serious Outcomes Surveillance Network of the Canadian Immunization Research Network	Public Health Agency of Canada	2021-04-01	2023-09-30	\$1,826,552.00
Nuu-chah-nulth Tribal Council COVID-19 Vaccine Study into Immune Response, Effectiveness, Safety	Public Health Agency of Canada	2021-04-01	2024-03-31	\$4,923,188.00
Safety and Efficacy of Protective COVID-19 Vaccines	Public Health Agency of Canada	2021-04-01	2023-09-30	\$1,170,824.00
COVID-19 vaccination in pregnancy: A province-wide epidemiological assessment of safety and effectiveness using the BORN Ontario Registry	Public Health Agency of Canada	2021-04-02	2023-03-31	\$798,134.00
Canadian Immunization Research Network Provincial Collaborative Network COVID-19 Vaccine Post-Market Studies	Public Health Agency of Canada	2021-04-03	2023-06-30	\$1,347,384.00
Characterization of COVID-19 vaccine safety epidemiology and safety signal detection for adverse events following immunization in Alberta.	Public Health Agency of Canada	2021-04-04	2023-06-30	\$176,150.00
Understanding Immune Responses to SARS_CoV-2 Infection and Vaccination in children aged 5-11 years: Expansion of existing CITF-supported pediatric studies (TARGet Kids!)	Public Health Agency of Canada	2021-11-01	2023-12-31	\$311,180.00
Understanding Immune Responses to SARS-CoV-2 Infection and Vaccination in children aged 5-11 years: Expansion of existing COVID-19 Immunity Monitoring Task Force-supported pediatric studies (CHILD COVID-19 Study – Edmonton)	Public Health Agency of Canada	2021-11-01	2023-09-30	\$85,705.00



CHILD Manitoba COVID-19 Immunity Monitoring Study - COVID-19 Immunity Monitoring Task Force	Public Health Agency of Canada	2021-11-01	2023-12-31	\$145,710.00
Understanding Immune Responses to SARS CoV 2 Infection and Vaccination in children aged 5 11 years: Expansion of existing CITF supported pediatric studies (SPRING)	Public Health Agency of Canada	2021-11-01	2023-12-31	\$999,297.00
Safety and immunogenicity of COVID-19 vaccines in pediatric autoimmune diseases (SUCCEED KIDS)	Public Health Agency of Canada	2022-01-04	2023-12-31	\$1,273,910.00

(b) which projects and departments researched manufacturers' COVID-19 vaccine applications and how much did each project cost, broken down by (i) vaccine name, (ii) project name, (iii) department name, (iv) start date, (v) completion date, (vi) cost?

The Public Health Agency of Canada did not undertake or fund research on manufacturers' COVID-19 vaccine applications.

(c) which projects and departments informed Canadians and specialists about the adverse events associated with the COVID-19 vaccines, broken down by (i) project name, (ii) department name, (iii) adverse event, (iv) start date, (v) completion date, (vi) date Canadians were informed about the adverse event, (vii) cost?

The COVID-19 Immunity Task Force generated the following research:

(i) Project Name	(ii) Department Name	(iii) Adverse Event	(iv) Start Date	(v) Completion Date	(vi) Date Canadian Were Informed about the Adverse Event	(vii) Cost
Sentinel surveillance for serious adverse events following immunization and assessment of COVID-19 vaccine effectiveness for the prevention of serious outcomes among hospitalized Canadian adults: A study of the Serious Outcomes Surveillance Network of the	Public Health Agency of Canada	Any Adverse Event Following COVID-19 Immunization	2021-04-01	2023-09-30	Not Applicable	\$1,826,552.00



Canadian Immunization Research Network						
Immunogenicity and adverse events following immunization with alternate schedules of authorized COVID-19 vaccines in Canada: is "mix and match" of the second dose safe and immunogenic	Public Health Agency of Canada	Any Adverse Event Following COVID-19 Immunization	2021-04-01	2023-09-30	Not Applicable	\$4,813,358.00
CANVAS: COVID Vaccine Active Safety Surveillance	Public Health Agency of Canada	Any Adverse Event Following COVID-19 Immunization	2021-04-01	2023-09-30	Not Applicable	\$6,863,814.00
Characterization of COVID-19 vaccine safety epidemiology and safety signal detection for adverse events following immunization in Alberta.	Public Health Agency of Canada	Any Adverse Event Following COVID-19 Immunization	2021-04-01	2023-06-30	Not Applicable	\$176,150.00

(d) which projects and departments researched vaccine hesitancy and how much did each project cost, broken down by (i) project name, (ii) department name, (iii) start date, (iv) completion date, (v) cost?

The COVID-19 Immunity Task Force generated the following research:

(i) Project Name	(ii) Department Name	(iii) Start Date	(iv) Completion Date	(v) Cost
Toward Enhancing COVID-19 Vaccine Confidence among African Canadians: Sustainability of Immune Responses and Safety Profiles	Public Health Agency of Canada	2021-04-01	2023-09-30	\$1,498,686.00
Vaccine Access, Uptake, Effectiveness and Safety in First Nations Communities	Public Health Agency of Canada	2021-04-01	2024-03-31	\$1,497,163.00
COVENANT: The COVID-19 Cohort Study of People Experiencing Homelessness in Toronto	Public Health Agency of Canada	2022-04-01	2023-12-31	\$207,170.00
Safety immUnogenicity of Covid-19 vaCcines in systEmic immunE mediated inflammatory Diseases	Public Health Agency of Canada	2021-04-01	2023-09-30	\$3,654,484.00

National cross-sectional survey of health workers perceptions of COVID-19 vaccine effectiveness, acceptance, and drivers of vaccine decision-making	Public Health Agency of Canada	2023-02-15	2023-11-24	\$295,579.75
The Impact of the Pandemic Experience on Future Vaccine-Related Intentions and Behaviours (2022)	Public Health Agency of Canada	2022 exact date to be confirmed	2022 exact date to be confirmed	\$171,545.30